Clinical differences between hospitalized patients with COVID-19-related pneumonia and those with influenza-related pneumonia during the omicron variant surge
Table 3.
Treatments and outcomes by group
|
|
|
COVID-19 pneumonia |
Flu pneumonia |
p value |
|
|
| Antiviral agents |
|
|
|
|
|
|
Remdesivir |
33 (71.7%) |
NA |
|
|
|
Ensitrelvir |
3 (7.8%) |
NA |
|
|
|
Molnupiravir |
8 (17.4%) |
NA |
|
|
|
Nilmatorelvir/Ritnavir |
2 (4.3%) |
NA |
|
|
|
Peramivir |
NA |
2 (33.3%) |
|
|
|
Oseltamivir |
NA |
2 (33.3%) |
|
|
|
Baloxavir marboxil |
NA |
1 (16.7%) |
|
|
|
Laninamivir |
NA |
1 (16.7%) |
|
|
| Antibiotics |
|
|
|
|
|
|
SBT/ABPC |
31 (67.4%) |
1 (16.7%) |
0.016* |
|
|
TAZ/PIPC |
9 (19.6%) |
1 (16.7%) |
0.333 |
|
|
LVFX |
2 (4.3%) |
1 (16.7%) |
0.224 |
|
|
CTRX |
2 (4.3%) |
1 (16.7%) |
0.224 |
|
|
VCM |
1 (2.2%) |
0 |
0.715 |
|
|
CAZ |
1 (2.2%) |
0 |
0.715 |
|
|
CEZ |
1 (2.2%) |
0 |
0.715 |
|
|
CMZ |
1 (2.2%) |
0 |
0.715 |
|
|
LSFX |
1 (2.2%) |
0 |
0.715 |
|
|
MEPM |
0 |
1 (16.7%) |
0.005** |
|
| Death |
|
7 (7/46=15.2%) |
0 |
0.304 |
|
|
|
|
